Who We Are

Rick Hiatt

• Global VP of Business Development for Siemens Healthcare’s Molecular Imaging Group
• President United Pharmacy Partners, a network of 50+ independent radiopharmacies
• VP of Business Logistics & Supplier Relations, Syncor International

Jack Coffey

• Previously Sr. VP of Quality & Regulatory for Cardinal Health Nuclear Pharmacy Services
• VP of Quality & Regulatory, Syncor International (now Cardinal Health)

Jamie Singer

• Previously Project Manager at Scientific Project Management, responsible for planning, budgeting and execution of outsourcing, quality assurance and quality control activities in support of regulatory filings
• Scientist at Pfizer Global R&D at Wyeth

Dave Casebier Ph.D.

• Formerly VP of CMC forNavidea Biopharmaceuticals, working on the successful US and EU approval of Lymphoseek and the implementation of commercial supply chain and development of Flutafuranol, NAV4694
• Senior VP at Tokai Pharmaceuticals, responsible for CMC
• Senior Director at BMSMI-Lantheus Medical Imaging, program leader, discovery and development of Flurpiridaz and LMI1195
• VP at ArQule Inc, responsible for foundational technology and creation of the Production and Engineering groups

Dave Smith

• Current owner, CycloSmith LLC
• Radiopharmacy Consultancy and America’s representative for ORA Sprl
• Previously, Director Technical Services, IBA Molecular
• General Manager, UPPI-PET PET Operations
• Senior Support Engineer, Radiopharmacy Americas, GE Healthcare
• Clinical Engineer, Wake Forest Univ.
• Clinical Research Coordinator at The Mayo Clinic and Oregon Health and Science Univ.

Joanna Shuping

Fifteen years in drug and device clinical research including roles of increasing responsibility at:

• Cardinal Health (Sr. Consultant)
• Devicor (SME Consultant)
• Navidea (Director, Clinical Research)
• Wake Forest Health Sciences, CCC and Dept. of Neurology (Project Manager)
• The Segal Institute (Site Director) and
• Piedmont Medical Research (Clinical Research Coordinator)

Courteney Gerken

Formerly:

• Project Manager, Ionis Pharmaceuticals
• Project Associate, Ionis Pharmaceuticals
• Executive Admin, Ionis Pharmaceuticals
• Education:
  Masters in Healthcare Administration
  Bachelors in Equestrian Science

Bill Abbott

• Previously in executive roles including VP Operations at Life Molecular Imaging (formally Piramal Imaging)
• President of Jubilant Draximage
• VP and General Manager of Nuclear Medicine at Bracco Diagnostics
• Upper level management positions with DuPont Pharma (now Lantheus Medical Imaging)
• Past Chair of the MITA PET Group industry forum

Stephen Arnold

• Previously, Diector, Finance CTI Molecular Imaging Inc.
• VP Finance AMETEK, Advanced Measurement Technology (NYSE: AME)
• CFO Sensus Healthcare Inc. (NASDAQ: SRTS).
• CFO ProNova Solutions

John Doumitt

• Previously, General Manager and CEO of HemaCare Corporation
• VP of Operations at Activus Medical Solutions
• Sr. Director of Operations Finance at Ingram Micro
• Director of Field Services at Syncor International (now Cardinal Health).

Habibi Mamone

• Previously President and CEO of SSCM, LLC (Supply Chain Management)
• Vice President of Greenbrier (Five Star Resort)
• Director of Logistics at Siemens

Sulantha Mathotaarachchi

• Expertise developing informatics platforms to manage and analyze healthcare data with machine learning
• 5 years of experience on software platforms and analytics in neuroimaging
• Computer Science and Engineering with Masters in Neuroscience from McGill Univ.

Thom Tulip Ph.D.

• Long experience in Medical Imaging Pharmaceuticals
• Held roles of increasing responsibility at DuPont, BMS, Lantheus, Alseres, Navidea (Pres.& COO) and Fluoropharma (Pres. & CEO)
• Established and led the multidisciplinary PET group at MITA (The Medical Imaging Technology Assn.)
• Serves on the Executive Comm. of MITA’s Board of Directors

Bruno Rossi

• Over twenty years of experience in the pharma in Japan and SE Asia with roles of increasing responsibility at Ciba-Geigy, Schering and Bayer in Japan, Switzerland and Singapore
• Developed the early strategy for florbetaben (amyloid PET tracer) and introduced Zevalin and Xofigo (oncology) in Japan
• Leading industry role with EFPIA in connection with the introduction of Health Technology Assessment in Japan
• Currently advising companies with a focus on business development and market access

Mas Tsuno

• Previously Deputy Chief Clinical Officer of Neurology Clinical Development of Eisai
• Over 40 years Pharma R&D experiences based in US, Europe and Japan having held multiple management positions at Eisai including global clinical development (President, Eisai Medical Research Inc.), R&D strategy and planning, pharmacovigilance, post-marketing surveillance.
• Experiences crossing multiple therapeutic areas (neurology, immunology, oncology, gastrointestinal and  cardiovascular)

Michael Reitermann

• More than 20 years in med-tech industry
• Board member of several med-tech companies

• Former member of Managing Board of Siemens Healthineers AG
• Former head of global commercial and service operations of Siemens Healthineers AG

• Former head of diagnostics division of Siemens Healthcare

• Former head of Molecular Imaging business of Siemens Healthcare

David Morehous

• Former Senior Counsel and lead global lawyer for Siemens Healthcare’s Molecular Imaging business unit
• Former Assistant General Counsel of CTI Molecular Imaging, through $1 billion acquisition by Siemens Medical Solutions

Chase Dearborn

Paul Graziano

• Over 25 years of experience in the Information Technology business, including business development and high-tech experience with Fortune 500 companies
• Developing innovative technology strategies, with particular expertise in Cloud computing integration and Strategic planning and development for Information Systems

Professor Serge Gauthier CM, N.D., FRCPC

McGill University

Alzheimer Disease and Related Disorders Research Unit, McGill Center for Studies in Aging, Douglas Research Centre and Professor, Departments of Neurology and Neurosurgery, and Psychiatry at McGill University, Quebec, Canada

Jeffrey L. Evelhoch Ph.D.,

Head of Translational Biomarkers, Merck, PA

Oskar Hansson M.D., Ph.D.

Clinical Memory Research, Lund University, Sweden

Richard Hargreaves Ph.D.

Currently Senior VP Head of Neuroscience TRC Research and Early Development at Myers Squibb. Previously Corporate VP, Head of Neuroscience and Imaging Research and Early Development at Celgene, VP, Head, New Indications Research Unit (NIRU) and Research & Early Development Centers of Excellence (RED-CoEs) at Biogen and VP Discovery Head for Neuroscience and VP Imaging in Merck Research Laboratories

Kenji Ishii, M.D.

Team for Neuroimaging Research Tokyo Metropolitan Institute of Gerontology, Japan

Keith Johnson M.D.

Molecular Neuroimaging, Massachusetts General Hospital, Neurologist, Memory Disorders Unit, Brigham and Women’s Hospital, Professor of Radiology, Harvard Medical School, MA.

Eric M Reiman M.D.

Banner Alzheimer’s Institute, Chief Executive Officer, Banner Research, Clinical Director of the Neurogenomics, Division at the Translational Genomics Research Institute, Professor of Psychiatry, University of Arizona and Director, Arizona Alzheimer’s Consortium, AZ

Professor Christopher Rowe FRACP M.D.., FRACP, FAANMS

Director of Molecular Imaging Research and a consultant neurologist to the Memory Disorders Clinic at the Austin Hospital, Australia

Koen Van Laere M.D., Ph.D., D.Sc

Nuclear Medicine and Molecular Imaging, PET-MR Unit, Full Professor, Department of Imaging and Pathology, University Hospital Leuven-KU Leuven, Belgium